Phase III Randomized Study of All-Trans Retinoic Acid versus Cytosine Arabinoside and Daunorubicin as Induction Therapy for Patients with Previously Untreated Acute Promyelocytic Leukemia

Determinants of fatal bleeding during induction chemotherapy for acute promyelocytic leukemia in the ATRA era

S Mantha;DA Goldman;J-W Lee;D Zannino;D Douer;H Iland;MR Litzow;EM Stein;FR Appelbaum;RA Larson;JM Rowe;MS Tallman Blood 124(21):948; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;

Telomere length recovery strongly predicts overall survival in acute promyelocytic leukemia (http://www.bloodjournal.org/content/124/21/2375)

M Baljevic;B Dumitriu;J-W Lee;E Paietta;J Racevskis;C Chen;E Stein;RE Gallagher;JM Rowe;F Appelbaum;B Powell;RA Larson;NS Young;M Tallman Blood 124(21):2375; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;

Late relapses following ALL-transretinoic acid for acute promyelocytic leukemia are uncommon, respond well to salvage therapy and occur independently of prognostic factors at diagnosis: longterm follow-up of North American Intergroup study 0129

D Douer;L Zickl;L Shepherd;C Willman;CD Bloomfield;JM Rowe;PH Wiernik;M Tallman Blood 118(21):abstract 83; American Society of Hematology Annual Meeting, oral presentation

Does microgranular variant morphology of acute promyelocytic leukemia independently predict for a less favorable outcome compared with classical M3 APL? A joint study of North American Intergroup and PETHEMA Group [PMID20858857;PMC3031411]

M Tallman;HT Kim;P Montesinos;F Appelbaum;J de la Serna;JM Bennett;G Deben;C Bloomfield;J Gonzalez;JH Feusner;M Gonzalez;RA Larson;J Gonzalez-San Miguel;A Ogden;G Milone;JM Rowe;C Rayon;L Shepherd;C Rivas;CA Schiffer;E Vallenga;PH Wiernik;CL Willman;MA Sanz Blood 116(25):5650-5659

Relapse of acute promyelocytic leukemia with PML-RARx mutant subclones independent of proximate all-trans retinoic acid selection pressure

RE Gallagher;E Schachter-Tokarz;DC Zhou;W Ding;SH Kim;BJ Sankoorikal;W Bi;KJ Livak;JL Slack;CL Willman Leukemia 20:556-562

Phase III trial of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL)

J Gregory;H Kim;T Alonzo;R Gerbing;A Ogden;W Woods;H Weinstein;L Shepherd;C Schiffer;F Appelbaum;CL Willman;P Wiernik;J Rowe;M Tallman;J Feusner Blood (ASH Annual Meeting Abstracts) 106(11):#894

Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group experience.

JM Rowe;X Li;PA Cassileth;FR Appelbaum;CA Schiffer;PH Wiernik;MR Litzow;LD Cripe;HM Lazarus;E Paietta;GW Dewald;HJ Weinstein;AK Ogden;WG Woods;L Shepherd;JH Feusner;CD Bloomfield;MS Tallman Blood 106(11): #546

Microgranular variant (M3V) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the atra era: a report of 153 patients treated on Intergroup 0129 and pethema LPA96 and LPA99.

MS Tallman;HT Kim;CA Schiffer;FR Appelbaum;JH Feusner;AK Ogden;L Shepherd;CL Willman;CD Bloomfield;JM Rowe;RA Larson;PH Wiernik;G Martin;C Rayon;J de la Serna;C Rivas;JD Gonzalez-San Miguel;G Deben;MA Sanz Blood 104(11): #394

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol

MS Tallman;JW Andersen;CA Schiffer;FR Appelbaum;JH Feusner;WG Woods;A Ogden;H Weinstein;L Shepherd;C Willman;CD Bloomfield;JM Rowe;PH Wiernik Blood 100(13):4298-4302

The significance of trisomy 8 in myeloid leukemia: a Southwest Oncology Group (SWOG) study.

ML Slovak;H Gundacker;SR Wolman;FR Appelbaum American Journal of Human Genetics 69(4):232(#285)

Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARa mRNA using real-time reverse-transcription polymerase chain reaction

JL Slack;W Bi;KJ Livak;N Beaubier;M Yu;M Clark;SH Kim;RE Gallagher;CL Willman Journal of Molecular Diagnostics 3(4):141-149

Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia

C Crump;C Chen;FR Appel baum;KJ Kopecky;SM Schwartz;CL Willman;ML Slovak;NS Weiss Cancer Epidemiology Biomarkers & Prevention 9:457-460

Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARa isoform: results from Intergroup protocol 0129

JL Slack;CL WIllman;JW Andersen;YP Li;DS Viswanatha;CD Bloomfield;MS Tallman;RE Gallagher Blood 95(2):398-403

Predictive value of automated, quantitative real-time RT-PCR performed at the end of consolidation of acute promyelocytic leukemia (APL): a SWOG, CALGB, and ECOG Intergroup study (INT-0129)

CL Willman;B Yeap;W Bi;JC Slack;DP Harrington;KJ Livak;FR Appelbaum;CD Bloomfield;MS Tallman;RE Gallagher Proc of the American Society of Clinical Oncology 19:5a(#9)

Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17)

JM Bennett;D Catovsky;MT Daniel;G Flandrin;D Galton;HR Gralnick;CL Willman Leukemia 14:1197-1200

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome results and prognostic factor analysis from intergroup protocol 0129

MS Tallman;JW Andersen;CA Schiffer;FR Appelbaum;JH Feusner;A Ogden;L Shepherd;C Willman;CD Bloomfield;JM Rowe;PH Wiernik Blood 94(10)Suppl.1:698a(#3086)part_1_of_2

Cell cycle arrest and therapeutic sensitivity in de novo AML.

D Banker;C Willman;M Groudine;F Appelbaum Blood 90(10)Suppl.1:67a(#290)

Association of PML-RARa fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study.

RE Gallagher;CL Willman;JL Slack;JW Andersen;Y Li;D Viswanatha;CD Bloomfield;FR Appelbaum;CA Schiffer;MS Tallman;PH Wiernik Blood 90(4):1656-1663

All-trans-retinoic acid in acute promyelocytic leukemia.

MS Tallman;JW Andersen;CA Schiffer;FR Appelbaum;JH Feusner;A Ogden;L Shepherd;CL Willman;CD Bloomfield;JM Rowe;PH Wiernik New England Journal of Medicine 337:1021-1028

Correlation of PML-RARa mRNA transcript type with morphology, cytogenetics and clinical parameters in actue promyelocytic leukemia.

D Viswanatha;KJ Kopecky;K Doss;C Rankin;DR Head;RE Magenis;FR Appelbaum;CL Willman Intl Academy of Pathology Book of Abstracts :125A(#730)

Molecular characteristics and clinical features of adult APL patients with the type V PML-RARa ISOFORM: Results from intergroup protocol 0129.

JL Slack;CL Willman;YP Li;D Viswanatha;CD Bloomfield;PH Wiernik;MS Tallman;RE Gallagher Blood 88(10)Suppl:635a(#2528)

Correlation of PML-RARa mRNA type with pretreatment clinical characteristics and achievement of complete remission (CR) in acute promyelocytic leukemia (APL): An Intergroup Laboratory study.

R Gallagher;C Willman;J Slack;J Andersen;Y Li;D Viswanatha;C Bloomfield;F Appelbaum;C Schiffer;M Tallman;P Wiernik Blood 86(10)(Suppl.1)(#2902):729a

Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL).

MS Tallman;J Andersen;CA Schiffer;FR Appelbaum;JE Feusner;WG Woods;A Ogden;H Weinstein;L Shepherd;JM Rowe;PH Wiernik Blood 86(10)(Suppl.1)(#488):125a